Please assess the completion status of the following clinical trial:

Trial Title: A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have signed written informed consent form voluntarily.~* Histologically or cytologically documented advanced solid tumor that is refractory/relapsed/intolerant to standard therapies, or for which no effective standard therapy is available, or subject refuses standard therapy.~* Have radiologically measurable disease based on RECIST 1.1~* ECOG of 0 or 1.~* Estimated life expectancy of ≥3 months.~* Adequate organ function.~* Have agreed to take effective contraception from the date of signing the informed consent form until 120 days after the last administration.~Exclusion Criteria:~* have been diagnosed other advanced tumors within 2 years before the first use of the study drug, except for the cured localized tumors.~* with active central nervous system metastasis, cancerous meningitis, or spinal cord compression.~* Prior use of any anti-VEGF or anti-VEGFR antibodies.~* Receipt of anti-tumor treatment, other study drug, major surgery, or serious infection within 4 weeks prior to C1D1 (Cycle 1 Day1, the first dose of study drug).~* Have received central venous catheterization within 7 days prior to C1D1.~* Severe or uncontrolled cardiovascular and cerebrovascular diseases.~* Uncontrolled hypertension.~* have a high risk of bleeding.~* Uncontrolled gastrointestinal diseases.~* Uncontrolled pleural/pericardial or peritoneal effusion.~* Have occurred any thromboembolic event, non-gastrointestinal fistula or female genital tract fistula within 6 monthsprior to C1D1.~* With cirrhosis of Child-Pugh B or C.~* Active or unstable viral hepatitis; or active tuberculosis.~* Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.~* received live vaccines prior 30 days within the first dose.~* take apart in other clinical studies at the same time.~* known to be allergic to any component of AK109, other monoclonal antibodies or any therapeutic protein.~* mental illness, drug abuse, or alcohol dependence that may affect compliance with the test requirements.~* Any treatment risk or condition that interferes with the study by the investigator judged.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AK109 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).